Which has preferable valuation & earnings, ALKS or GERN?

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.67B 4.62 $241.66M $0.38 120.97 Geron $183.88M 4.72 -$83.50M -$0.11 N/A

Is ALKS or GERN more profitable?

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Geron -34.17% -24.48% -10.30%

Does the media favor ALKS or GERN?

In the previous week, Alkermes had 4 more articles in the media than Geron. MarketBeat recorded 6 mentions for Alkermes and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat Alkermes' score of 0.99 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is DYN or GERN more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Geron -34.17% -24.48% -10.30%

Does the media refer more to DYN or GERN?

In the previous week, Dyne Therapeutics had 33 more articles in the media than Geron. MarketBeat recorded 35 mentions for Dyne Therapeutics and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat Dyne Therapeutics' score of 0.31 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, VCYT or GERN?

Veracyte has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 6.35 $66.35M $1.41 28.99 Geron $183.88M 4.72 -$83.50M -$0.11 N/A

Is VCYT or GERN more profitable?

Veracyte has a net margin of 20.37% compared to Geron's net margin of -34.17%. Veracyte's return on equity of 9.26% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 20.37% 9.26% 8.61% Geron -34.17% -24.48% -10.30%

Does the media prefer VCYT or GERN?

In the previous week, Veracyte had 4 more articles in the media than Geron. MarketBeat recorded 6 mentions for Veracyte and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat Veracyte's score of 0.44 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, GRAL or GERN?

Geron has higher revenue and earnings than GRAIL. Geron is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A Geron $183.88M 4.72 -$83.50M -$0.11 N/A

Is GRAL or GERN more profitable?

Geron has a net margin of -34.17% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Geron -34.17% -24.48% -10.30%

Does the media favor GRAL or GERN?

In the previous week, GRAIL had 7 more articles in the media than Geron. MarketBeat recorded 9 mentions for GRAIL and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat GRAIL's score of 0.96 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor DNLI or GERN?

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Geron's average media sentiment score of 1.70 beat Denali Therapeutics' score of 1.46 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Geron (GERN) Competitors

$1.35 -0.02 (-1.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.01 (+1.11%)

As of 09/11/2026 07:59 PM Eastern

Compare

GERN vs. ALKS, DYN, VCYT, GRAL, and DNLI

Should you buy Geron stock or one of its competitors? Geron's main competitors and comparable companies include Alkermes (ALKS), Dyne Therapeutics (DYN), Veracyte (VCYT), GRAIL (GRAL), and Denali Therapeutics (DNLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Geron	-34.17%	-24.48%	-10.30%

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Alkermes currently has a consensus target price of $54.56, indicating a potential upside of 18.69%. Geron has a consensus target price of $4.00, indicating a potential upside of 196.30%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.62	$241.66M	$0.38	120.97
Geron	$183.88M	4.72	-$83.50M	-$0.11	N/A

In the previous week, Alkermes had 4 more articles in the media than Geron. MarketBeat recorded 6 mentions for Alkermes and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat Alkermes' score of 0.99 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Alkermes beats Geron on 13 of the 17 factors compared between the two stocks.

How does Geron compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Geron has higher revenue and earnings than Dyne Therapeutics. Geron is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Geron	$183.88M	4.72	-$83.50M	-$0.11	N/A

Dyne Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Geron	-34.17%	-24.48%	-10.30%

Dyne Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Dyne Therapeutics currently has a consensus price target of $32.17, suggesting a potential upside of 76.64%. Geron has a consensus price target of $4.00, suggesting a potential upside of 196.30%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Dyne Therapeutics had 33 more articles in the media than Geron. MarketBeat recorded 35 mentions for Dyne Therapeutics and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat Dyne Therapeutics' score of 0.31 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Dyne Therapeutics beats Geron on 9 of the 16 factors compared between the two stocks.

How does Geron compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

In the previous week, Veracyte had 4 more articles in the media than Geron. MarketBeat recorded 6 mentions for Veracyte and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat Veracyte's score of 0.44 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Veracyte presently has a consensus target price of $55.78, suggesting a potential upside of 36.48%. Geron has a consensus target price of $4.00, suggesting a potential upside of 196.30%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Veracyte has a net margin of 20.37% compared to Geron's net margin of -34.17%. Veracyte's return on equity of 9.26% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Geron	-34.17%	-24.48%	-10.30%

Veracyte has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Veracyte has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99
Geron	$183.88M	4.72	-$83.50M	-$0.11	N/A

73.7% of Geron shares are held by institutional investors. 1.6% of Veracyte shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Veracyte beats Geron on 13 of the 17 factors compared between the two stocks.

How does Geron compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

73.7% of Geron shares are owned by institutional investors. 1.8% of GRAIL shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Geron has a net margin of -34.17% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Geron	-34.17%	-24.48%	-10.30%

Geron has higher revenue and earnings than GRAIL. Geron is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A
Geron	$183.88M	4.72	-$83.50M	-$0.11	N/A

GRAIL has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, GRAIL had 7 more articles in the media than Geron. MarketBeat recorded 9 mentions for GRAIL and 2 mentions for Geron. Geron's average media sentiment score of 1.70 beat GRAIL's score of 0.96 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

GRAIL presently has a consensus price target of $71.11, indicating a potential downside of 6.72%. Geron has a consensus price target of $4.00, indicating a potential upside of 196.30%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

GRAIL beats Geron on 9 of the 17 factors compared between the two stocks.

How does Geron compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Geron	-34.17%	-24.48%	-10.30%

Geron has lower revenue, but higher earnings than Denali Therapeutics. Geron is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A
Geron	$183.88M	4.72	-$83.50M	-$0.11	N/A

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Geron's average media sentiment score of 1.70 beat Denali Therapeutics' score of 1.46 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Denali Therapeutics presently has a consensus price target of $35.85, suggesting a potential upside of 69.97%. Geron has a consensus price target of $4.00, suggesting a potential upside of 196.30%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics beats Geron on 9 of the 15 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$880.19M	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-12.27	14.25	275.24	25.29
Price / Sales	4.72	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	3.86	15.12	10.33	6.20
Net Income	-$83.50M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-14.01%	-4.34%	-3.32%	-2.35%
1 Month Performance	-14.01%	-0.02%	-0.41%	-2.77%
1 Year Performance	6.30%	40.64%	19.21%	7.63%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	1.8271 of 5 stars	$1.35 -1.5%	$4.00 +196.3%	+2.3%	$880.19M	$183.88M	N/A	70	Positive News
ALKS Alkermes	2.8632 of 5 stars	$46.11 +1.6%	$54.56 +18.3%	+65.9%	$7.62B	$1.48B	121.35	2,050	News Coverage
DYN Dyne Therapeutics	3.1057 of 5 stars	$18.42 -4.0%	$32.17 +74.6%	+38.2%	$3.58B	N/A	N/A	100	Analyst Forecast Insider Trade Options Volume
VCYT Veracyte	4.3682 of 5 stars	$42.03 -4.2%	$55.78 +32.7%	+28.3%	$3.53B	$517.15M	29.81	790	Analyst Upgrade
GRAL GRAIL	0.6883 of 5 stars	$77.56 +0.1%	$71.11 -8.3%	+97.2%	$3.46B	$147.17M	N/A	1,360	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors